株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の分子診断市場:第7版 (感染症分子診断、癌分子診断、NAT血液スクリーニング、移植分子診断、組織/細胞分子診断、遺伝性疾患分子診断)

The World Market for Molecular Diagnostics, 7th Edition (Infectious Disease, Cancer, NAT Blood Screening, Transplantation, Histology/Cytology, Inherited Diseases)

発行 Kalorama Information 商品コード 172533
出版日 ページ情報 英文 353 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.35円で換算しております。
Back to Top
世界の分子診断市場:第7版 (感染症分子診断、癌分子診断、NAT血液スクリーニング、移植分子診断、組織/細胞分子診断、遺伝性疾患分子診断) The World Market for Molecular Diagnostics, 7th Edition (Infectious Disease, Cancer, NAT Blood Screening, Transplantation, Histology/Cytology, Inherited Diseases)
出版日: 2017年01月30日 ページ情報: 英文 353 Pages
概要

当レポートでは、世界の分子診断市場の現状と見通しを調査分析し、臨床分子診断の概説、臨床分子診断の主要アプリケーション (感染症診断、輸血診断、組織/細胞診断、癌診断、移植診断など) の分析、および主要企業のプロファイルなどを提供提供しています。

第1章 エグゼクティブサマリー

第2章 臨床分子診断のイントロダクション

  • イントロダクション
  • 核酸増幅検査 (NAAT) 技術
  • マイクロアレイ
  • in situ ハイブリダイゼーション (ISH)
  • シーケンシング
  • 結論

第3章 医療における分子診断

  • イントロダクション
  • 分子診断の医療費償還環境
  • 分子診断・臨床ユーティリティ基準
  • 薬事未承認検査 (LDT) の普及
  • 結論

第4章 感染症分子診断市場

  • 市場分析
  • CT/NG, HPVおよび女性の健康
  • 肝炎院内感染
  • HIV
  • 医療関連感染 (HAI) および敗血症
  • 呼吸器
  • 結核
  • 結論

第5章 輸血分子診断市場

  • イントロダクション
  • 市場分析
  • 新たな感染症の脅威・アッセイの導入
  • 結論

第6章 組織学・細胞学の分子診断市場

  • イントロダクション
  • 市場分析
  • 分子組織学におけるRNA
  • CISHおよびその他の試薬の化学的性質
  • 出生前検診が出生前遺伝学的検査 (NIPT) へ
  • 結論

第7章 癌分子診断市場

  • イントロダクション
  • 分子分解能を癌診断へ
  • 組織利用診断、コンパニオンアッセイおよびIVDにおける現状
  • 市場分析
  • 米国市場
  • EU市場
  • 中国市場
  • その他 (RoW) 市場
  • 結論

第8章 移植分子診断市場

  • イントロダクション
  • 市場分析
  • 次世代シーケンシングおよびリアルタイムPCRへの技術的な移行
  • 結論

第9章 遺伝性疾患分子診断市場

  • 市場分析
  • 血栓性素因および凝固マーカー
  • 自閉症
  • アルツハイマー病
  • 心血管疾患
  • 糖尿病
  • 精神疾患
  • 胃腸の調子
  • その他の自己免疫疾患
  • 結論

第10章 分子診断市場のサマリー・主な結論

  • 市場サマリー
  • 主な結論

第11章 企業プロファイル

  • ABBOTT DIAGNOSTICS
  • ADVANCED CELL DIAGNOSTICS
  • AFFYMETRIX (THERMO FISHER SCIENTIFIC)
  • AGILENT TECHNOLOGIES
  • ALERE
  • AMOY DIAGNOSTICS
  • APPLIED SPECTRAL IMAGING
  • BECKMAN COULTER (DANAHER)
  • BECTON, DICKINSON & CO. (BD)
  • BEIJING GENOMICS INSTITUTE (BGI)
  • BERRY GENOMICS
  • BIOCARTIS
  • BIO-RAD LABORATORIES
  • BIOVIEW
  • CAREDX
  • CEPHEID (DANAHER)
  • COVARIS
  • DAKO (AGILENT TECHNOLOGIES)
  • EIKEN CHEMICAL
  • EPIGENOMICS
  • EXOSOME DIAGNOSTICS
  • GENMARK DIAGNOSTICS
  • GRIFOLS
  • HOLOGIC
  • ILLUMINA
  • IMMUCOR
  • JANSSEN DIAGNOSTICS (JOHNSON & JOHNSON)
  • LEICA BIOSYSTEMS (DANAHER)
  • LUMINEX CORPORATION
  • MERIDIAN BIOSCIENCE
  • NANOSTRING TECHNOLOGIES
  • QIAGEN
  • QUIDEL
  • ROCHE DIAGNOSTICS
  • SIEMENS HEALTHCARE DIAGNOSTICS
  • THERMO FISHER SCIENTIFIC
  • VELA DIAGNOSTICS
  • VENTANA MEDICAL SYSTEMS (ROCHE)

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI15232978

Clinical molecular diagnostics has delivered on its promise in healthcare, demonstrating revenue growth at more than twice the rest of the IVD market. Molecular diagnostics now represents more than one-tenth of the global IVD market with a growth trajectory secured through platform innovation in lower-cost nucleic acid amplification tests (NAATs) and clinical next-generation sequencing (NGS). Kalorama Information's The World Market for Molecular Diagnostics is now in its 7th Edition, providing an independent and authoritative view of this important market segment in clinical testing. Once esoteric, molecular tests have become routine and expanded to all levels of healthcare - from the pathology lab all the way to the doctor's office and clinics of the developing world. Kalorama Information analyst Emil Salazar details the status of the molecular diagnostics market, as it stands in 2017.

Detailed Market Analysis Provides Needed Business Planning Information

The market analysis in this report includes molecular diagnostics the relevant test kits, other reagents and instruments that are used for clinical testing are projected to outperform the overall in vitro diagnostics (IVD) market. As part of its coverage, the following market estimates are included in this report:

  • Molecular Diagnostics for Infectious Disease Market, 2016-2021
  • Molecular Diagnostics for Cancer Market 2016-2021
  • Molecular Diagnostics for NAT Blood Screening Market 2016-2012
  • Molecular Diagnostics for Hepatitis Market
  • HIV Molecular Diagnostics Market, 2016 to 2021
  • HAIs/Sepsis Molecular Diagnostics Market, 2016 to 2021
  • CT/NG Molecular Diagnostics Market, 2016 to 2021
  • HPV Molecular Diagnostics Market, 2016 to 2021
  • Respiratory Molecular Diagnostics Market, 2016 to 2021
  • Mycobacteria/TB Molecular Diagnostics Market, 2016 to 2021
  • Other Infectious Disease Molecular Diagnostics Market, 2016 to 2021
  • in situ hybridization (ISH) Market by Application: Genetic, Cancer, Other, 2016 to 2021
  • Other Histology Molecular Diagnostics Market, 2016 to 2021
  • Inherited Diseases Molecular Diagnostics Market, 2016 to 2021
  • Transplant Diagnostics Molecular Diagnostics Market, 2016 to 2021

The major applications of clinical molecular diagnostics include: Infectious disease diagnostics such as molecular microbiology and virology, including the detection, identification, quantification and nucleic-acid based resistance or susceptibility profiling of pathogens; Blood Transfusion Diagnostics, nucleic acid screening (NAT) of donated blood, often pooled samples, for the detection of active infections responsible for transfusion transmitted infections (TTIs); ancillary market for molecular immunohematology or blood typing; Histology / cytology diagnostics , which is largely synonymous with in situ hybridization (ISH) methods that use direct hybridization of chromogenic (CISH) or fluorescent (FISH) nucleic acid probes within slided tissue or suspended cell samples viewed under microscopy; Molecular Cancer Diagnostics, which are tissue, blood and urine samples can be assayed using nucleic acid amplification tests (NAATs) or sequencing to diagnose, prognose and identify key mutations for targeted therapies; future; Transplant diagnostics - various PCR-based methodologies, Sanger sequencing and NGS used to type HLA alleles in low to high resolution in order to match donors and recipients for solid organ and hematopoietic stem cell (HSCT) or bone marrow transplants, as well as post-transplant monitoring. The report also covers Inherited disease diagnostics - diagnosis of rare genetic diseases and other inherited traits including pharmacodiagnostic (pharmacokinetic) traits; major area of application is thrombophilia markers and anticoagulant response markers

Market Share by Test Segment and Global Market Breakouts

There are a great number of companies participating in these segments of molecular diagnostics, from molecular specialists to the top-tier IVD companies. This report offers superior detail, identifying market share not only for the overall molecular diagnostics market but for molecular test categories, including:

  • Molecular Blood Testing Market Share Analysis
  • Molecular Cancer Testing Market Share Analysis
  • Molecular Transplantation Market Share Analysis
  • Molecular Infectious Disease Market Share Analysis
  • Inherited Disease Testing Market Share Analysis

The segmented market share allows competitors and interested market-watchers to see not only how a company is performing in the overall molecular diagnostics market, but also in their specialty area. To assist in global business planning efforts, this report contains market sizing and forecasts to 2021 for major world regions including the United States, Europe, Japan, China and Latin America. Data in the report includes:

  • Molecular Blood Screening Geographic Market Segmentation ( United States, Europe, Japan, China, Latin America, Rest of World)
  • Molecular Cancer Testing Market Share ( United States, Europe, Japan, China, Latin America, Rest of World)
  • Molecular Transplantation Market Share ( United States, Europe, Japan, China, Latin America, Rest of World)
  • Molecular Infectious Disease Market Share ( United States, Europe, Japan, China, Latin America, Rest of World)
  • Inherited Disease Testing Market Share ( United States, Europe, Japan, China, Latin America, Rest of World)

Global market numbers allow companies to plan future expansion and find markets for growth.

The future of the molecular diagnostics market lies with nucleic acid amplification tests and sequencing-based tests. Time to results for real-time PCR and isothermal amplification are crucial for several infectious disease testing applications including respiratory testing, hospital-acquired infections, bloodstream infections, and molecular point-of-care tests. These trends are discussed in the report.

Superior Company Profiling

Kalorama Information reports are designed to be focused on real world industry activities, rather than mere hypothetical business models. This makes company profiles important, as they provide a foundation for understanding what is happening in a market, and what has changed recently. This report contains profiles of major companies competing in molecular diagnostics. For each company, revenues, market share, products on the market and acquisitions and other deals are detailed. The following companies are profiled in the report:

  • Abbott Diagnostics
  • Advanced Cell Diagnostics
  • Affymetrix (Thermo Fisher Scientific)
  • Agilent Technologies
  • Alere
  • Amoy Diagnostics
  • Applied Spectral Imaging
  • Beckman Coulter (Danaher)
  • Becton, Dickinson & Co. (BD)
  • Beijing Genomics Institute (BGI)
  • Berry Genomics
  • Biocartis
  • bioMérieux
  • Bio-Rad Laboratories
  • Cepheid (Danaher)
  • Covaris
  • Dako (Agilent Technologies)
  • Eiken Chemical
  • Epigenomics
  • Exosome Diagnostics
  • Genmark Diagnostics
  • Grifols
  • Hologic
  • Illumina
  • Immucor
  • Janssen Diagnostics (Johnson & Johnson)
  • Leica Biosystems (Danaher)
  • Luminex Corporation
  • Meridian Bioscience
  • Nanosphere (Luminex)
  • Nanostring Technologies
  • Qiagen
  • Quidel
  • Roche Diagnostics
  • Siemens Healthcare Diagnostics
  • Thermo Fisher Scientific
  • Vela Diagnostics
  • Ventana Medical Systems (Roche)

Table of Contents

1: EXECUTIVE SUMMARY

  • INTRODUCTION
  • MOLECULAR DIAGNOSTIC TECHNOLOGIES
  • MOLECULAR DIAGNOSTICS IN HEALTHCARE
  • GLOBAL MOLECULAR DIAGNOSTICS MARKET
  • Table 1-1: Global Molecular Diagnostics Market (2016-2021) - Infectious Disease, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Disease
  • Figure 1-1: Global Molecular Diagnostics Market (2016) - Infectious Disease, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases
  • Figure 1-2: Global Molecular Diagnostics Market (2016-2021) - Infectious Disease, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases
  • Table 1-2: Global Molecular Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 1-3: Global Molecular Diagnostics Market (2016) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 1-4: Global Molecular Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • MAJOR CONCLUSIONS

2: INTRODUCTION TO CLINICAL MOLECULAR DIAGNOSTICS

  • INTRODUCTION
  • NUCLEIC ACID AMPLIFICATION TEST (NAAT) TECHNOLOGIES
  • Real-Time PCR (qPCR)
  • Isothermal Amplification
  • Table 2-1: Selected Isothermal Amplification Methods and Platform Examples
  • Trends in Nucleic Acid Amplification Testing and Emerging Technologies
  • MICROARRAYS
  • Table 2-2: Selected Clinical Array Component and Microarray Systems
  • Trends in Microarray Testing
  • IN SITU HYBRIDIZATION (ISH)
  • Table 2-3: Selected Commercial In Situ Hybridization (ISH) Tests
  • Trends in In Situ Hybridization Testing
  • SEQUENCING
  • Table 2-4: Selected Clinical Next-Generation Sequencing Platforms
  • Trends in Clinical Sequencing
  • CONCLUSIONS

3: MOLECULAR DIAGNOSTICS IN HEALTHCARE

  • INTRODUCTION
  • REIMBURSEMENT ENVIRONMENT FOR MOLECULAR DIAGNOSTICS
  • MOLECULAR DIAGNOSTICS AND THE CLINICAL UTILITY STANDARD
  • LABORATORY-DEVELOPED TESTS ARE HERE TO STAY
  • CONCLUSIONS

4: MARKET FOR MOLECULAR INFECTIOUS DISEASE DIAGNOSTICS

  • Table 4-1: Market-Available Molecular Diagnostic Platforms - POC, Hospital and Developing World (Vendor, Assay Menu, Planned Assays, Regulatory Status, Procedure Integration, Test Principles)
  • MARKET ANALYSIS
  • Table 4-2: Global Molecular Infectious Disease Diagnostics Market (2016-2021) - Hepatitis, HIV, HAIs/Sepsis, CT/NG, HPV, Respiratory, Mycobacteria/TB, Other
  • Figure 4-1: Global Molecular Infectious Disease Diagnostics Market (2016) - Hepatitis, HIV, HAIs/Sepsis, CT/NG, HPV, Respiratory, Mycobacteria/TB, Other
  • Figure 4-2: Global Molecular Infectious Disease Diagnostics Market (2016-2021) - Hepatitis, HIV, HAIs/Sepsis, CT/NG, HPV, Respiratory, Mycobacteria/TB, Other
  • Table 4-3: Global Molecular Infectious Disease Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 4-3: Global Molecular Infectious Disease Diagnostics Market (2016) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 4-4: Global Molecular Infectious Disease Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 4-5: Global Molecular Infectious Disease Diagnostics Market Share - Abbott Diagnostics, BD, bioMérieux, Cepheid, Hologic, Qiagen, Roche Diagnostics, Siemens Healthcare Diagnostics, Others (%)
  • CT/NG, HPV AND WOMEN'S HEALTH
  • HEPATITIS
  • HIV
  • HOSPITAL-ACQUIRED INFECTIONS (HAIS) AND SEPSIS
  • RESPIRATORY
  • TUBERCULOSIS
  • CONCLUSIONS

5: MARKET FOR MOLECULAR BLOOD TRANSFUSION DIAGNOSTICS

  • INTRODUCTION
  • MARKET ANALYSIS
  • Table 5-1: Global NAT Blood Screening Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 5-1: Global NAT Blood Screening Market (2016) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 5-2: Global NAT Blood Screening Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • Table 5-2: Commonly Tested Pathogens in Blood Screening
  • Figure 5-3: Global NAT Blood Screening Share (%)
  • NEW INFECTIOUS DISEASE THREATS AND ASSAY INTRODUCTION
  • CONCLUSIONS

6: MARKET FOR MOLECULAR HISTOLOGY AND CYTOLOGY DIAGNOSTICS

  • INTRODUCTION
  • MARKET ANALYSIS
  • Table 6-1: Global Molecular Histology Diagnostics Market (ISH, Other Direct Hybridization) by Application (2016-2021) - Genetic Disorders, Cancer, Other/Infectious
  • Figure 6-1: Global Molecular Histology Diagnostics Market (ISH, Other Direct Hybridization) by Application (2016) - Genetic Disorders, Cancer, Other/Infectious
  • Figure 6-2: Global Molecular Histology Diagnostics Market (ISH, Other Direct Hybridization) by Application (2016-2021) - Genetic Disorders, Cancer, Other/Infectious
  • Table 6-2: Global Molecular Histology Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 6-3: Global Molecular Histology Diagnostics Market (2016) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 6-4: Global Molecular Histology Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • RNA IN MOLECULAR HISTOLOGY
  • CISH AND OTHER REAGENT CHEMISTRIES
  • PRENATAL TESTING MOVES TO NIPT
  • CONCLUSIONS

7: MARKET FOR MOLECULAR CANCER DIAGNOSTICS

  • INTRODUCTION
  • BRINGING MOLECULAR RESOLUTION TO CANCER DIAGNOSTICS
  • TISSUE-BASED DIAGNOSTICS, COMPANION ASSAYS AND THE STATUS QUO IN IVD
  • Table 7-1: Major Molecular Companion and Complementary Assays for Cancer
  • MARKET ANALYSIS
  • Table 7-2: Global Molecular Cancer Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 7-1: Global Molecular Cancer Diagnostics Market (2016) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 7-2: Global Molecular Cancer Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 7-3: Global Molecular Cancer Diagnostics Market Share (%)
  • U.S. MARKET
  • EU MARKET
  • CHINESE MARKET
  • REST OF THE WORLD
  • CONCLUSIONS

8: MARKET FOR MOLECULAR TRANSPLANT DIAGNOSTICS

  • INTRODUCTION
  • MARKET ANALYSIS
  • Table 8-1: Global Molecular Transplant Diagnostics Market (2016-2021) - United States, Europe, Japan, Rest of World
  • Figure 8-1: Global Molecular Transplant Diagnostics Market (2016) - United States, Europe, Japan, Rest of World
  • Figure 8-2: Global Molecular Transplant Diagnostics Market (2016-2021) - United States, Europe, Japan, Rest of World
  • Figure 8-3: Global Molecular Transplant Diagnostics Market Share
  • TECHNOLOGICAL SHIFT TO NEXT-GENERATION SEQUENCING AND REAL-TIME PCR
  • CONCLUSIONS

9: MARKET FOR MOLECULAR DIAGNOSTICS IN INHERITED DISEASES

  • MARKET ANALYSIS
  • Table 9-1: Global Molecular Diagnostics Market in Inherited Diseases (2016-2021) - United States, Europe, Rest of World
  • Figure 9-1: Global Molecular Diagnostics Market in Inherited Diseases (2016) - United States, Europe, Rest of World
  • Figure 9-2: Global Molecular Diagnostics Market in Inherited Diseases (2016-2021) - United States, Europe, Rest of World
  • THROMBOPHILIA AND COAGULATION MARKERS
  • AUTISM
  • ALZHEIMER'S DISEASE
  • CARDIOVASCULAR DISEASE
  • DIABETES
  • PSYCHIATRIC DISORDERS
  • GASTROINTESTINAL CONDITIONS
  • OTHER AUTOIMMUNE DISEASES
  • CONCLUSIONS

10: MOLECULAR DIAGNOSTICS MARKET SUMMARY AND MAJOR CONCLUSIONS

  • MARKET SUMMARY
  • Table 10-1: Global Molecular Diagnostics Market (2016-2021) - Infectious Disease, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases
  • Figure 10-1: Global Molecular Diagnostics Market (2016) - Infectious Disease, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases
  • Figure 10-2: Global Molecular Diagnostics Market (2016-2021) - Infectious Disease, Blood Screening, Histology, Cancer Assays, Transplant, Inherited Diseases
  • Table 10-2: Global Molecular Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 10-3: Global Molecular Diagnostics Market (2016) - United States, Europe, Japan, China, Latin America, Rest of World
  • Figure 10-4: Global Molecular Diagnostics Market (2016-2021) - United States, Europe, Japan, China, Latin America, Rest of World
  • MAJOR CONCLUSIONS

11: COMPANY PROFILES

  • ABBOTT DIAGNOSTICS
  • Table 11-1: Abbott Diagnostics Revenue (2013-2016)
  • Infectious Diseases/qPCR
  • Cytogenetics/Oncology/FISH
  • Molecular ID/AST
  • ADVANCED CELL DIAGNOSTICS
  • AFFYMETRIX (THERMO FISHER SCIENTIFIC)
  • Table 11-2: Affymetrix Revenue (2013-2016)
  • AGILENT TECHNOLOGIES
  • Table 11-3: Agilent Technologies Revenue (FY 2013-FY 2016)
  • ALERE
  • Table 11-4: Alere Revenue (2013- 2016)
  • AMOY DIAGNOSTICS
  • APPLIED SPECTRAL IMAGING
  • BECKMAN COULTER (DANAHER)
  • BECTON, DICKINSON & CO. (BD)
  • Table 11-5: Becton, Dickinson & Co. (BD) Revenue (FY 2013-FY 2016)
  • Molecular
  • Histology/Cytology
  • Flow Cytometry
  • BEIJING GENOMICS INSTITUTE (BGI)
  • BERRY GENOMICS
  • BIOCARTIS
  • Table 11-6: Biocartis Revenue (2013-2016)
  • BIOMÉRIEUX
  • Table 11-7: bioMérieux Revenue (2013-2016)
  • Molecular
  • Sequencing
  • BIO-RAD LABORATORIES
  • Transplant Diagnostics
  • Molecular Diagnostic QC Products
  • Sequencing
  • BIOVIEW
  • Table 11-8: BioView Revenue (2013-2016)
  • CAREDX
  • Sequencing
  • Molecular HLA Typing
  • CEPHEID (DANAHER)
  • Table 11-9: Cepheid Revenue (2013-2016)
  • Molecular Hospital-Acquired Infection (HAI) Testing
  • Molecular Sexual Health and Women's Health Testing
  • Molecular Critical Infectious Disease Testing
  • Molecular Oncology Testing
  • COVARIS
  • DAKO (AGILENT TECHNOLOGIES)
  • Table 11-10: Dako Revenue (2013-2016)
  • EIKEN CHEMICAL
  • Table 11-11: Eiken Chemical Revenue (FY 2013-FY 2016)
  • EPIGENOMICS
  • Table 11-12: Epigenomics Revenue (2013-2016)
  • EXOSOME DIAGNOSTICS
  • GENMARK DIAGNOSTICS
  • Table 11-13: GenMark Diagnostics Revenue (2013-2016)
  • GRIFOLS
  • Table 11-14: Grifols Diagnostic Revenue (2013-2016)
  • Molecular Immunohematology and Specialty Testing Services
  • NAT Blood Screening
  • HOLOGIC
  • Table 11-15: Hologic Revenue (FY 2013-FY 2016)
  • Molecular Cytology / Histology (HPV)
  • Other Molecular (STIs, HIV, HCV, TB, Respiratory)
  • Microbiology (AccuProbe Molecular Culture ID Tests)
  • ILLUMINA
  • Table 11-16: Illumina Revenue (2013-2016)
  • Sequencing
  • Translational Research
  • Clinical Assay Development
  • Industry Lab-Developed Tests
  • Arrays
  • IMMUCOR
  • Table 11-17: Leica Biosystems Revenue (FY 2013-FY 2016)
  • Transfusion Diagnostics
  • Transplant Diagnostics
  • Immucor Dx Laboratory Service
  • JANSSEN DIAGNOSTICS (JOHNSON & JOHNSON)
  • LEICA BIOSYSTEMS (DANAHER)
  • Table 11-18: Leica Biosystems Revenue (2013-2016)
  • LUMINEX CORPORATION
  • Table 11-19: Luminex Corporation Revenue (2013- 2016)
  • Business Expansion
  • MAGPIX Multiplexing
  • ARIES Molecular System
  • MERIDIAN BIOSCIENCE
  • Table 11-20: Meridian Bioscience Revenue (FY 2013-FY 2016)
  • NANOSPHERE (LUMINEX)
  • Table 11-21: Nanosphere Revenue (2013-2016)
  • NANOSTRING TECHNOLOGIES
  • Table 11-22: NanoString Technologies Revenue (2013-2016)
  • Clinical Diagnostics
  • Companion Assay Development
  • Research Platforms
  • Sequencing
  • QIAGEN
  • Table 11-23: Qiagen Revenue (2013-2016)
  • Molecular Infectious Disease
  • Cancer Diagnostics
  • Transplant Diagnostics
  • Next-Generation Sequencing
  • Circulating Tumor Cells
  • QUIDEL
  • Table 11-24: Quidel Revenue (2013-2016)
  • ROCHE DIAGNOSTICS
  • Table 11-25: Roche Diagnostics Revenue (2013-2016)
  • Molecular Diagnostics
  • Blood Screening
  • Sequencing
  • Liquid Biopsy
  • Microbiology
  • SIEMENS HEALTHCARE DIAGNOSTICS
  • THERMO FISHER SCIENTIFIC
  • Table 11-26: Thermo Fisher Scientific Revenue (2013-2016)
  • Transplant Diagnostics
  • qPCR
  • Sequencing
  • VELA DIAGNOSTICS
  • VENTANA MEDICAL SYSTEMS (ROCHE)
  • Table 11-27: Ventana Medical Systems Revenue (2013-2016)
Back to Top